Equillium_Square_Logo.png
Equillium Announces Closing of Public Offering of Common Stock
August 18, 2020 16:05 ET | Equillium
LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders,...
Equillium_Square_Logo.png
Clinical Trial Shows Itolizumab Reduces Mortality in Patients Hospitalized with COVID-19
July 13, 2020 03:30 ET | Equillium
Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon Biocon has received emergency use approval from Drugs Controller General of...
Equillium_Square_Logo.png
Equillium to Present at Jefferies Virtual Healthcare Conference
May 21, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium Reports First Quarter 2020 Financial Results
May 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium_Square_Logo.png
Equillium Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Business Update
March 26, 2020 16:07 ET | Equillium
EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic Company Reaffirms Guidance to Report Initial Data from the EQUATE Trial in Acute GVHD in 2H 2020 LA JOLLA, Calif., March ...
Equillium_Square_Logo.png
Equillium Strengthens Leadership Team with Key Appointments
February 27, 2020 16:13 ET | Equillium
Maple Fung, M.D., joins as vice president clinical developmentMatthew Ritter, Ph.D., joins as vice president corporate development LA JOLLA, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Equillium,...
Equillium_Square_Logo.png
Equillium to Present at 9th Annual SVB Leerink Global Healthcare Conference
February 13, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to...
Equillium_Square_Logo.png
Equillium to Present Translational Preclinical Data Demonstrating Increased Survival and Decreased Disease Severity in Models of Graft-Versus-Host Disease Treated with Itolizumab at the Transplantation & Cellular Therapy Meetings of ASTCT & CIBMTR
January 29, 2020 16:07 ET | Equillium
LA JOLLA, Calif., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...
Equillium Logo.png
Equillium & Biocon Expand Exclusive Licensing Agreement for Itolizumab to Include Australia and New Zealand
December 12, 2019 07:00 ET | Equillium; Biocon Ltd
LA JOLLA, Calif. and BENGALURU, India, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop...
Equillium_FullColor_RGB-300 - transparent.png
Equillium to Present Translational Data on Itolizumab for Acute Graft-Versus-Host Disease at 61st American Society of Hematology (ASH) Annual Meeting and Exposition
November 26, 2019 16:07 ET | Equillium
LA JOLLA, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat...